Followers | 1320 |
Posts | 26906 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Tuesday, January 21, 2020 7:40:54 AM
TransEnterix Announces Klinikum Esslingen to Initiate a Senhance Surgical System Program
6:55 AM ET 1/21/20 | BusinessWire
Related Quotes
8:00 PM ET 1/17/20
Symbol Last % Chg
TRXC
1.49 0.00%
Real time quote.
https://www.klinikum-esslingen.de/
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--January 21, 2020--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Klinikum Esslingen, a hospital in southern Germany close to Stuttgart, has entered into an agreement to lease and utilize a Senhance(R) System. The Senhance System has been installed at the hospital facility and cases are expected to begin shortly. This placement is one of the two placements referenced in the Company's January 6, 2020 press release.
Klinikum Esslingen is a major German hospital that serves as the academic teaching hospital of the University of Tübingen. The facility has more than 660 beds and performs more than 9,000 surgical interventions each year.
The Senhance(R) Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, eye-sensing camera control and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.
"We are committed to support and grow the outstanding minimally invasive surgical program of Klinikum Esslingen with the addition of a Senhance System," said Anthony Fernando, president and chief executive officer at TransEnterix. "We continue to see strong momentum in Germany, and the expansion into such a prestigious hospital as the Klinikum Esslingen is a significant milestone in the advancement of digital laparoscopy with Senhance in Europe."
"We have created a strong, multidisciplinary program in minimally invasive surgery at our hospital," said Professor Dr. Ludger Staib, chief physician of the clinic for general and visceral surgery at the Klinikum Esslingen. "We believe modern technology can help offer our patients the most precise and least invasive surgery possible, and we appreciate the ability to build on our strong existing minimally invasive program with the Senhance that will allow for maximum precision, visualization and control during delicate surgeries."
About TransEnterix
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries. For more information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance System and the Klinikum Esslingen hospital initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether TransEnterix will continue to see strong momentum in Germany, whether the expansion of the Senhance System into Klinikum Esslingen will serve as a significant milestone in the advancement of digital laparoscopy in Europe, and whether the use of a Senhance System in the minimally invasive program at Klinikum Esslingen will allow for maximum precision, visualization and control during delicate surgeries. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 27, 2019 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005296/en/
CONTACT: For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
SOURCE: TransEnterix, Inc.
Copyright Business Wire 2020
> Dow Jones Newswires
January 21, 2020 06:55 ET (11:55 GMT)
Recent ASXC News
- Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG • GlobeNewswire Inc. • 04/03/2024 12:45:00 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023 • GlobeNewswire Inc. • 03/21/2024 08:05:00 PM
- U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines • IH Market News • 03/21/2024 11:26:38 AM
- Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 10:55:00 AM
- Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference • GlobeNewswire Inc. • 02/28/2024 11:55:00 AM
- Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals • GlobeNewswire Inc. • 02/27/2024 11:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:01:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 12:00:04 AM
- Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 01/16/2024 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:21 AM
- Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update • GlobeNewswire Inc. • 01/08/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:45:21 PM
- Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System • GlobeNewswire Inc. • 01/04/2024 09:15:00 PM
- Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 11:55:00 AM
- Asensus Announces Sale of Senhance Robotic System in Romania • GlobeNewswire Inc. • 12/20/2023 11:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 11:26:08 PM
- Senhance Robotic System Sold by Asensus Surgical • GlobeNewswire Inc. • 12/04/2023 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:32 PM
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023 • GlobeNewswire Inc. • 11/14/2023 09:05:00 PM
- Asensus Surgical Announces Sale of Senhance Robotic System • GlobeNewswire Inc. • 11/14/2023 11:55:00 AM
- Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 11:55:00 AM
- Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program • GlobeNewswire Inc. • 11/06/2023 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2023 10:55:13 AM
- Asensus Surgical Announces Collaboration with NVIDIA to Enhance Augmented Intelligence Capabilities of the ISU • GlobeNewswire Inc. • 09/07/2023 10:55:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM